-

11:06:14 PM

OCX Stock News

OCX - Oncocyte Corporation

06/01/23 4:15 PM

Nasdaq : OCX

conferences

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Oncocyte Corporation (NASDAQ: OCX) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies,

RHEA-AI

neutral

05/11/23 8:00 AM

Nasdaq : OCX

earnings

Oncocyte Reports First Quarter 2023 Financial Results

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the first quarter 2023, ended March 31, 2023. First Quarter 2023 and Recent Highlights:

RHEA-AI

negative

04/27/23 4:59 PM

Nasdaq : OCX

earnings

Oncocyte To Announce First Quarter 2023 Financial Results

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023,

RHEA-AI

neutral

04/18/23 8:45 AM

Nasdaq : OCX

Oncocyte Presents New Data at AACR

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that five posters of original research are being presented at the Annual Meeting of the American Association for Cancer Research. Four abstracts explore the

RHEA-AI

neutral

04/12/23 4:15 PM

Nasdaq : OCX

Oncocyte Announces Reduction in Force

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving approximately 20% of its workforce, which management believes will extend Oncocyte’s cash runway in 2024. “As part of our efforts

RHEA-AI

neutral

04/07/23 8:24 AM

Nasdaq : OCX

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO™ to samples collected from the randomized Phase II AtezoTRIBE clinical trial in

RHEA-AI

neutral

04/03/23 8:00 AM

Nasdaq : OCX

offering

Oncocyte Pricing of $13.86 Million Public Offering of Common Stock

Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company, announced today the entry into an agreement with certain members of the Company’s board of directors,

RHEA-AI

neutral

03/31/23 5:00 PM

Nasdaq : OCX

earnings

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced plans to file a Form 12b-25 with the U.S. Securities and Exchange Commission regarding its Annual Report on Form 10-K and reports preliminary financial results

RHEA-AI

neutral

03/29/23 4:01 PM

Nasdaq : OCX

earnings

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earnings conference call. It will now report its fourth quarter and full year 2022 financial results on

RHEA-AI

neutral

03/15/23 4:01 PM

Nasdaq : OCX

earnings

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its fourth quarter and full year 2022 financial results on Wednesday, March 29, 2023. In conjunction with the release, Oncocyte will host a

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

OCX Data

IndustryIn-Vitro Diagnostic Substance Manufacturing
Websitewww.oncocyte.com
Security nameOncocyte Corporation
Issue typecs
SectorManufacturing
Sic code2835
Employees76
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- In-Vitro Diagnostic Substance Manufacturing
Address15 Cushing
StateCalifornia
CityIrvine
Zip92618
CountryUS
Phone19494097600

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company's tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte has launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO™, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company previously announced its planned acquisition of Chronix Biomedical Inc. and its TheraSure™ CNI Monitor test, and also plans to continue with the development of DetermaMx™ as the Company seeks to expand into the blood-based monitoring market. Oncocyte's pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.